scholarly journals Type I collagen improves skin symptoms in late-phase diffuse cutaneous systemic sclerosis

2008 ◽  
Vol 4 (9) ◽  
pp. 448-448
Keyword(s):  
Systemic Sclerosis ◽  
Type I Collagen ◽  
Late Phase ◽  
Type I ◽  
Skin Symptoms ◽  
Diffuse Cutaneous Systemic Sclerosis

scholarly journals Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis

2014 ◽  
Vol 42 (2) ◽  
pp. 236-242 ◽  
Author(s):  
Corrie L. Poelman ◽  
Laura K. Hummers ◽  
Fredrick M. Wigley ◽  
Cynthia Anderson ◽  
Francesco Boin ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Intravenous Immunoglobulin ◽  
Randomized Clinical Trials ◽  
Type I Collagen ◽  
T Test ◽  
Type I ◽  
Single Center Experience ◽  
Paired Student ◽  
Diffuse Cutaneous Systemic Sclerosis ◽  
The Mean

Objective.We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc).Methods.The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test.Results.Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p < 0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (−5.3 ± 7.9) compared to the relaxin trial (−4.8 ± 6.99, p = 0.74) or MMF group (−3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (−8 ± 8.3) than in the D-pen (−2.47 ± 8.6, p = 0.005) and collagen (−3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (−7.1 ± 9, p = 0.67).Conclusion.Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.

CORRELATIONS BETWEEN CLINICAL MEASUREMENT IN SYSTEMIC SCLEROSIS (SSC) AND IMMUNE RESPONSE TO TYPE I COLLAGEN (CI).

2004 ◽  
Vol 52 ◽  
pp. S286-S287
Author(s):  
A E Postlethwaite ◽  
W K Wong ◽  
J Ingels ◽  
A H Kang ◽  
P Clements ◽  
...  
Keyword(s):  
Immune Response ◽  
Systemic Sclerosis ◽  
Type I Collagen ◽  
Type I ◽  
Clinical Measurement

Association of Functional Microsatellites in the Human Type I Collagen α2 Chain (COL1A2) Gene with Systemic Sclerosis

2000 ◽  
Vol 272 (1) ◽  
pp. 36-40 ◽  
Author(s):  
Ryu-Ichiro Hata ◽  
Jun Akai ◽  
Akinori Kimura ◽  
Osamu Ishikawa ◽  
Masataka Kuwana ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Type I Collagen ◽  
Type I ◽  
Human Type ◽  
Col1a2 Gene

scholarly journals Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis

2014 ◽  
Vol 67 (1) ◽  
pp. 243-253 ◽  
Author(s):  
Markella Ponticos ◽  
Ioannis Papaioannou ◽  
Shiwen Xu ◽  
Alan M. Holmes ◽  
Korsa Khan ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Type I Collagen ◽  
Type I ◽  
Dermal Fibrosis
Sign in / Sign up

Export Citation Format

Share Document